

Accreditation and Designation Statements and Disclosure Report

LUGPA 2025 CME Program: Operationalizing the Science -Translating New Concepts into Clinical Practice

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the LUGPA. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint Medical Education Institute designates the live and enduring formats for this educational activity for a maximum of *4.25 AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activities.

The live approval period is: November 6, 2025

The enduring approval period is: December 18, 2025 – December 18, 2028

Financial Disclosures.

The following planners, speakers, reviewers or staff have relevant financial relationships to disclose:

“I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies.”

Full Legal Name	Commercial Interest	Role	Level of participation in the activity
Ronney Abaza	VTI, Conmed, Veracyte Covidien	Independent Contractor Advisor	
Piyush Agarwal	UroGen, Janssen, Ferring Engene CG Oncology	Consultant Advisor Researcher/Investigator	Speaker
David Albala	Exact Sciences, Applied Medical, Bio-Techne	Consultant	Speaker
Pedro Barata	Ipsen, AstraZeneca, AVEO Oncology, Johnson & Johnson, Pfizer, Bayer, Eisai, Astellas, Caris Life Sciences, Exelixis, Sanofi		Speaker
Gordon Brown	Dendreon, Pfizer, MDX Health, Bayer, AstraZeneca, Janssen, Ferring, Astellas, Merck	Consultant	Planner- Reviewer

Julio Davalos	Boston Scientific	Consultant	Speaker
David Ellis	Urogen, Lantheus, Cardinal Health, Verity Pharmaceuticals, Telix, Pfizer, Summitomo, Astellas, Fallon Medical,	Advisory	Speaker
Jason Hafron	Norvartis, Urogen, Bayer, Myriad AstraZeneca, Merck, Astellas, Dendreon, Janssen Blue Earth Diagnostics	Consultant Researcher/Investigator Speaker	Planner-Reviewer
Tom Jayram	Calyxo Inc Janssen, Ferring Specialty Networks/Cardinal, AZ Merck	Consultant Speakers Bureau Advisor Research Funding	Speaker
Matthew Love	Johnson & Johnson	Consultant	Speaker
Benjamin Lowentritt	Pfizer, Caris Johnson & Johnson, Bayer Dendreon, Novartis, Sumitomo	Advisor Consultant Researcher/Investigator	Speaker
Joshua Meeks	Immunity Bio, Photocure, Pfizer, Prokarium, CG Oncology, Astellas, Merck, Calibr, BMS, AZ, Protara UroGen, Imvax	Advisor Consultant	Speaker
Suzanne Merrill	Pfizer, EnGene, Johnson & Johnson Photocure, UroGen	Advisor Consultant	Speaker
Martin Miner	Tolmar Halozyme HiMS, Verity	Editorial Support Consultant Advisor	Speaker
David Morris	Pfizer, Cleveland Diagnostics, Merck, Blue Earth, Myriad, Bayer, Dendreon. AZ, Merck Clarity AZ, Myriad, Merck	Consultant Researcher/Investigator Speaker	
Ryan Nelson	Lexion Medical, Intuitive Surgical	Consultant	Speaker
Steven Rowe	Lantheus, Imaging Endpoints D&D Pharmatech	Consultant Ownership Interest	Speaker
Jeffery Spier	Novartis, Caris, Cardinal, Pfizer, Boston Scientific	Advisor	Speaker

These financial relationship(s) with ineligible companies have been mitigated by PeerPoint Medical Education Institute and the LUPGA.

All other presenters, planners, editors, or staff report no relationships to disclose:

"I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies."

This activity was supported by unrestricted grants from Ferring, AstraZeneca, Pfizer, Blue Earth, Lantheus and Calyxo.